A comparative analysis of persistence of advanced therapies among patients with inflammatory bowel disease in Taiwan

Of the 511 patients, 210 had ulcerative colitis (UC) and 301 had Crohn's disease (CD). UST showed the highest 52-week persistence in CD (91.08 %), followed by ADA (81.94 %), IFX (73.76 %), and VDZ (64.35 %), with a statistically significant difference (p < 0.001). In UC, UST also had the highest persistence rate (78.95 %), though this did not reach statistical significance (p = 0.083). IFX had the highest discontinuation rate due to side effects (5.9 %) CONCLUSIONS: UST showed superior 52-week persistence in CD patients, though it also had the highest rate of dose escalation. IFX had the highest rate of discontinuation due to side effects.